4.7 Review

MDPV and alpha-PVP use in humans: The twisted sisters

期刊

NEUROPHARMACOLOGY
卷 134, 期 -, 页码 65-72

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2017.10.007

关键词

Alpha-PVP; MDPV; Synthetic cathinones; New psychoactive substances; Adverse effects; Fatalities

资金

  1. BMS Otsuka
  2. Lundbeck
  3. Gillead
  4. Shering Plough
  5. Eutherapie
  6. Merck/Serono
  7. Astra Zeneca
  8. Janssen-Cilag
  9. Bouchara Recordati Pharmaceuticals
  10. Shire
  11. Indivior
  12. Bristol-Myers-Squibb
  13. Merck-Serono Pharmaceuticals

向作者/读者索取更多资源

The new psychoactive substances phenomenon continues to represent a considerable public health challenge. Synthetic cathinones are beta-keto amphetamine analogues, also known as legal highs, research chemicals, bath salts. These drugs have surfaced as a popular alternative to other illicit drugs of abuse, such as cocaine, MDMA, and methamphetamine, due to their potent psychostimulant and empathogenic effects. Pyrovalerone cathinones (a-pyrrolidinophenones) form a distinct group of designer cathinones, such as MDPV. After being listed as an illegal product, second generation compounds such as alpha-PVP, sharing a very similar chemical structure with MDPV, were developed. Clinical effects of these compounds are individual, dose- and route of administration-dependent. Both of them have been involved in an increased number of, not only acute intoxications but also fatalities over the past few years, raising concerns in the medical field. In this paper, we will review the available data regarding the use and effects of MDPV and alpha-PVP in humans in order to highlight their impact on public health. Health actors and general population need to be clearly informed of potential risks and consequences of these 2 novel psychoactive substances spread and use. The literature search conducted led to the identification of potentially 83 relevant articles. All articles were screened from their abstracts to determine their relevance in the framework of the current review. This article is part of the Special Issue entitled 'Designer Drugs and Legal Highs.' (C) 2017 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据